Findings

What do systematic reviews say?

396 questions · 408 findings · 34 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 113 · 27.7%GRADE not reported 40 · 9.8%Very low 91 · 22.3%Low 105 · 25.7%Moderate 50 · 12.3%High 9 · 2.2%

Intervention not reported

Health‐related quality of life · people at risk for the development of type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Socioeconomic effects · people at risk for the development of type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

All‐cause mortality · people at risk for the development of type 2 diabetes mellitus

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9306 participants
Moderate

Intervention not reported

Incidence of type 2 diabetes mellitus Defined as: fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) or a 2‐hour blood glucose after a glucose‐load test ≥ 11.1 mmol/L (200 mg/dL) or by an adjudication committeeb · people at risk for the development of type 2 diabetes mellitus

1 finding from 1 review

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons… 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 9306 participants
Moderate

Intervention not reported

rhIGF‐I, 0.1 mg/kg/day ‐ survival at12 months · patients with amyotrophic lateral sclerosis/motor neuron disease

1 finding from 1 review

Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor… 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 690 participants
Low

Intervention not reported

rhIGF‐I, 0.1 mg/kg/day ‐ change in AALSRS at 9 months · patients with amyotrophic lateral sclerosis/motor neuron disease

1 finding from 1 review

Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor… 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 357 participants
Low

Intervention not reported

rhIGF‐I, 0.1 mg/kg/day ‐ change in SIP after 9 months · patients with amyotrophic lateral sclerosis/motor neuron disease

1 finding from 1 review

Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor… 2012 · Cochrane Headline outcomes only
no estimate extracted
156 participants
Low

Intervention not reported

rhIGF‐I, all doses ‐ injection site pain · patients with amyotrophic lateral sclerosis/motor neuron disease

1 finding from 1 review

Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor… 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 449 participants
Low

Intervention not reported

rhIGF‐I, all doses ‐ injection site inflammation/reaction · patients with amyotrophic lateral sclerosis/motor neuron disease

1 finding from 1 review

Recombinant human insulin‐like growth factor I (rhIGF‐I) for the treatment of amyotrophic lateral sclerosis/motor… 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 779 participants
Low

Intervention not reported

Morbidity · Patients with type 2 diabetes mellitus

The review found no eligible studies for this question.

1 finding from 1 review

Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life · Patients with type 2 diabetes mellitus

1 finding from 1 review

Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 523 participants
Moderate

Intervention not reported

Well‐being · Patients with type 2 diabetes mellitus

1 finding from 1 review

Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin 2012 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 928 participants
Moderate

Intervention not reported

Patient satisfaction · Patients with type 2 diabetes mellitus

1 finding from 1 review

Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin 2012 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 928 participants
Moderate

Intervention not reported

Hypoglycaemic episodes · Patients with type 2 diabetes mellitus

1 finding from 1 review

Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin 2012 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 2492 participants
Moderate

Intervention not reported

Costs · Patients with type 2 diabetes mellitus

1 finding from 1 review

Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 514 participants
Moderate

Intervention not reported

HbA1c [%] · Patients with type 2 diabetes mellitus

1 finding from 1 review

Self‐monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin 2012 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 2324 participants
Moderate